What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.
|
Company |
Jan. 25 |
Weekly Gain |
My Watchlist |
|---|---|---|---|
|
Netflix (NFLX -0.62%) |
$169.56 |
71% |
|
|
ACADIA Pharmaceuticals (ACAD 0.64%) |
$6.15 |
19% |
|
|
Sarepta Therapeutics (SRPT 0.51%) |
$27.91 |
16% |
|
|
Green Mountain Coffee (GMCR.DL) |
$46.31 |
14% |
|
|
Research In Motion (BB 1.10%) |
$17.54 |
11% |
Source: Barron's.
Netflix was last week's biggest winner, soaring 71% after stunning investors with a healthy quarterly profit in its latest quarter. The leading video provider also closed out the year with healthy subscriber growth and a robust outlook for the current quarter.
ACADIA inched higher every single day last week. Jim Cramer's blessing along the way only helped the biotech. "You want to buy, buy, buy ACADIA," Cramer said during Tuesday night's Mad Money lightning round, echoing the sentiment of bulls who are hopeful over the company's promising Parkinson's treatment.
Sarepta Therapeutics moved up after Cowen initiated coverage on the biotech company with an "outperform" rating. Sarepta's treatment for Duchenne muscular dystrophy has performed well through its early clinical trials.
Green Mountain Coffee Roasters was also percolating nicely last week. Shares of the company behind the Keurig single-cup brewer posted double-digit gains after receiving a favorable report from a KeyBanc analyst.
Research In Motion rallied after its CEO told a German newspaper that the BlackBerry maker may be open to licensing its mobile operating system. RIM also revealed by the end of the week that it will have an ad in next weekend's Super Bowl game.
